News
10-07-2013, 11:00 AM
Immutep S.A., the biopharmaceutical company specializing in immuno-oncology, and Eddingpharm have entered into an agreement regarding the development, commercialization and manufacturing of Immutep’s ImmuFact IMP321.
More... (http://www.news-medical.net/news/20131007/Immutep-Eddingpharm-partner-to-develop-and-commercialize-ImmuFact-IMP321.aspx)
More... (http://www.news-medical.net/news/20131007/Immutep-Eddingpharm-partner-to-develop-and-commercialize-ImmuFact-IMP321.aspx)